Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.
Komal L. Jhaveri, MD
Advertisement
Articles by Komal L. Jhaveri, MD
Komal L. Jhaveri, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses T-DM1 for neoadjuvant breast cancer treatment.
Advertisement
Latest Updated Articles
Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast CancerPublished: May 24th 2018 | Updated:
Dr. Jhaveri on T-DM1 in the Neoadjuvant SettingPublished: February 21st 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5